VARIANT NBS SICKLE CELL PROGRAM REAGENT KIT, VARIANT NBS NEWBORN SCREENING SYSTEM AND VARIANT NBS WORKSTATION WITH

K080911 · Bio-Rad Laboratories Inc., Clinical Systems Divisi · GKA · May 2, 2008 · Hematology

Device Facts

Record IDK080911
Device NameVARIANT NBS SICKLE CELL PROGRAM REAGENT KIT, VARIANT NBS NEWBORN SCREENING SYSTEM AND VARIANT NBS WORKSTATION WITH
ApplicantBio-Rad Laboratories Inc., Clinical Systems Divisi
Product CodeGKA · Hematology
Decision DateMay 2, 2008
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 864.7415
Device ClassClass 2
AttributesPediatric

Indications for Use

The Bio-Rad VARIANT™nbs Sickle Cell Program is intended as a qualitative screen for the presence of hemoglobins F, A, S, D, C, and E in eluates of neonatal blood collected on filter paper by high-performance liquid chromatography (HPLC). The Bio-Rad VARIANTnbs Sickle Cell Program is intended for Professional Use Only. For In Vitro Diagnostic Use. The Bio-Rad VARIANTnbs Sickle Cell Program is for use only with the Bio-Rad VARIANTnbs Newborn Screening System.

Device Story

The VARIANTnbs Sickle Cell Program is an in vitro diagnostic system for neonatal screening. It utilizes high-performance liquid chromatography (HPLC) with a cation exchange cartridge to separate and identify hemoglobin variants (F, A, S, D, C, E) from neonatal blood samples collected on filter paper. The system is operated by professionals in a clinical laboratory setting. The Genetic Data Management (GDM) 3.0 software manages the workflow, including worklist setup, barcode reading, and data representation. The software upgrade from GDM 2.01 to 3.0 enables operation on the Microsoft Windows XP operating system and introduces features like an Archive Viewer and improved worklist flexibility. Healthcare providers use the output to identify infants with sickle cell disease or trait, facilitating early clinical intervention with prophylactic penicillin to improve patient outcomes.

Clinical Evidence

No clinical data; substantial equivalence based on design control activities, risk analysis, and verification/validation of software/OS modifications.

Technological Characteristics

Software-based genetic data management system; runs on Microsoft Windows XP; utilizes ObjectStore version 6.2 for data management; GDM software version 3.0.

Indications for Use

Indicated for qualitative screening of hemoglobins F, A, S, D, C, and E in neonatal blood eluates to detect hemoglobin S (HbS), which is indicative of sickle cell disease or sickle cell trait. Early diagnosis (prior to four months) allows for prophylactic penicillin treatment to reduce morbidity and mortality.

Regulatory Classification

Identification

An abnormal hemoglobin assay is a device consisting of the reagents, apparatus, instrumentation, and controls necessary to isolate and identify abnormal genetically determined hemoglobin types.

Special Controls

*Classification.* Class II (special controls). A control intended for use with an abnormal hemoglobin assay is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.

Related Devices

Submission Summary (Full Text)

{0} SPECIAL 510(k): Device Modification ODE Review Memorandum To: THE FILE RE: DOCUMENT NUMBER K080911 This 510(k) submission contains information/data on modifications made to the SUBMITTER'S own Class II, Class III or Class I devices requiring 510(k). The following items are present and acceptable (delete/add items as necessary): 1. The name and 510(k) number of the SUBMITTER'S previously cleared device. (For a preamendments device, a statement to this effect has been provided.) 2. Submitter's statement that the INDICATION/INTENDED USE of the modified device as described in its labeling HAS NOT CHANGED along with the proposed labeling which includes instructions for use, package labeling, and, if available, advertisements or promotional materials. 3. A description of the device MODIFICATION(S), including clearly labeled diagrams, engineering drawings, photographs, user's and/or service manuals in sufficient detail to demonstrate that the FUNDAMENTAL SCIENTIFIC TECHNOLOGY of the modified device has not changed. The change was for the upgrade of the Genetic Data Management (GDM) software from version 2.01 to version 3.0. This upgrade includes a change in the operating system from Windows NT to Windows XP. Comparison Information (similarities and differences) to applicant's legally marketed predicate device including, labeling, intended use, physical characteristics, and stability. The difference is that the operating system will be Genetic Data Management (GDM) version 3.0 run on Microsoft Windows XP, and an upgrade to ObjectStore version 6.2 for data management. 4. A Design Control Activities Summary which includes: a) Identification of Risk Analysis method(s) used to assess the impact of the modification on the device and its components, and the results of the analysis b) Based on the Risk Analysis, an identification of the verification and/or validation activities required, including methods or tests used and acceptance criteria to be applied c) A declaration of conformity with design controls. The declaration of conformity should include: i) A statement signed by the individual responsible, that, as required by the risk analysis, all verification and validation activities were performed by the designated individual(s) and the results demonstrated that the predetermined acceptance criteria were met, and ii) A statement signed by the individual responsible, that the manufacturing facility is in conformance with design control procedure requirements as specified in 21 CFR 820.30 and the records are available for review. 5. A Truthful and Accurate Statement, a 510(k) Summary or Statement and the Indications for Use Enclosure (and Class III Summary for Class III devices). The labeling for this modified subject device has been reviewed to verify that the indication/intended use for the device is unaffected by the modification. In addition, the submitter's description of the particular modification(s) and the comparative information between the modified and unmodified devices demonstrate that the fundamental scientific technology has not changed. The submitter has provided the design control information as specified in The New 510(k) Paradigm and on this basis, I recommend the device be determined substantially equivalent to the previously cleared (or their preamendment) device. (Reviewer's Signature) (Date) Comments Revised: 3/27/98
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...